Combining antibody markers for serosurveillance of SARS-CoV-2 to estimate seroprevalence and time-since-infection
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Serosurveillance is an important epidemiologic tool for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), used to estimate infection rates and the degree of population immunity. There is no general agreement on which antibody biomarker(s) should be used, especially with the rollout of vaccines globally. Here, we used random forest models to demonstrate that a single spike or receptor-binding domain (RBD) antibody was adequate for classifying prior infection, while a combination of two antibody biomarkers performed better than any single marker for estimating time-since-infection. Nucleocapsid antibodies performed worse than spike or RBD antibodies for classification, but can be useful for estimating time-since-infection, and in distinguishing infection-induced from vaccine-induced responses. Our analysis has the potential to inform the design of serosurveys for SARS-CoV-2, including decisions regarding a number of antibody biomarkers measured.
Article activity feed
-
-
SciScore for 10.1101/2021.09.06.21261175: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources Antibody responses examined included IgG, IgM and IgA responses against spike (S), receptor binding domain (R) and nucleocapsid (N) antigens as determined by ELISA or Luminex multiplex bead assays. S), receptor binding domain (Rsuggested: NoneUsing antibody biomarkers measured at different time points post-infection and those collected before the SARS-CoV-2 pandemic, we evaluated the importance and performance of IgG, IgM and IgA antibody isotypes against the nucleocapsid (N), the spike surface protein (S) and receptor binding domain (R) antigens in 1) identifying previously infected individuals, and … SciScore for 10.1101/2021.09.06.21261175: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources Antibody responses examined included IgG, IgM and IgA responses against spike (S), receptor binding domain (R) and nucleocapsid (N) antigens as determined by ELISA or Luminex multiplex bead assays. S), receptor binding domain (Rsuggested: NoneUsing antibody biomarkers measured at different time points post-infection and those collected before the SARS-CoV-2 pandemic, we evaluated the importance and performance of IgG, IgM and IgA antibody isotypes against the nucleocapsid (N), the spike surface protein (S) and receptor binding domain (R) antigens in 1) identifying previously infected individuals, and 2) their time since infection. IgAsuggested: Nonespike surface protein (S) and receptor binding domain (R) antigens in 1suggested: NoneResults from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There were a number of limitations in this analysis. The lack of longitudinal immune responses and lack of detailed time-since-infection data that may have led to larger error predicting time-since-infection. Our analysis was limited to studies of adults in high-income countries, and thus our results cannot be generalized to low- and middle-income countries, or to pediatric populations, and underscore the need for a better understanding of the kinetics of SARS-CoV-2 antibody responses across diverse populations. Despite this, our findings contribute towards informing the choice of antibody responses for seroepidemiological investigations of SARS-CoV-2.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
